The Swiss Innovation Park offers abc biopply and its pharma and biotech partners an ideal environment for close, collaborative in-vitro studies in early drug discovery. The proximity of pharma and biotech companies in the Basel life sciences region to abc biopply’s new organoid service laboratory allows drug developers easy outsourcing and personal access to an unique organoid competence center — limiting the use of resources and risk.

At the core of the offering is abc biopply’s proprietary NAM 3D CoSeedis Multi‑Organoid in chip technology. It enables the use of fully scalable, physiologically relevant, and yet highly standardized organoid models for early drug discovery. Customers benefit from reproducible, validated, and IND‑relevant in‑vitro study results.

“The experience of recent years clearly shows that complex organoid models only lead to IND‑relevant and robust outcomes when they are used under standardized, controlled, and scientifically validated conditions,” says Arne Faisst, CEO of abc biopply. “Our Organoid Competence Center ensures exactly these conditions and makes them accessible to our pharma and biotech partners through our integrated services.”

With its expansion into Basel, abc biopply strengthens its position as a leading provider of innovative, scalable, and translationally relevant organoid CRO services for preclinical research — supporting pharmaceutical companies worldwide in making better, earlier, and more reliably predictive decisions, while simultaneously reducing the use of animal models.